focus -WSS

focus

author：focus 2025-10-02 15:43:33 - browse：8871

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Deposition: Sackler embraced plan to conceal OxyContin’s strength

WSS

Extensive review finds private equity owners jack up cost of care

Extensive review finds private equity owners jack up cost of care

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

STAT Virtual Event: ASCO Recap, Live!

Stanford president’s abrupt resignation sparks debate

A new ‘biological computer' targets cancer while sparing healthy cells

focus

focus

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

A new ‘biological computer' targets cancer while sparing healthy cells

Hollywood unions extend contract negotiations for actors

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

The cancer drug shortage isn’t new — and neither are the solutions

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Jerome Adams on the need for new antivirals for Covid

After a decade, new Gardasil ad campaign gets it (mostly) right

Peter Hotez and the public health issue of online harassment

US jobless claims fall again as labor market continues to flash strength

leisure time

Moderna says combo Covid

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Health care court cases: Humana, Sutter, Novant

Statins may not be needed by millions of people, study suggests

When a patient nears the end, a feared therapy can comfort

entertainment

leisure time

explore

explore